STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has ...

STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and ...

Biosynex SA (FR:ALBIO) has released an update. Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test ...

Biosynex SA (FR:ALBIO) has released an update. Biosynex SA, a leader in health diagnostics, reported a turnover of €93 million in 2023 and has expanded its international presence with subsidiaries in ...

Biosynex is gearing up to acquire Chembio for $17.2 million in an all-cash transaction. The deal is expected to close in 1Q23. Each company specializes in point-of-care diagnostic tests for the ...

A manufacturer of rapid diagnostic tests in Hauppauge has paid $500,000 to end an investigation by the U.S. Securities and Exchange Commission, according to a securities filing. Chembio Diagnostics ...

A financially strapped Hauppauge-based manufacturer of diagnostic tests is being purchased by a French test maker for $17.2 million in cash, officials said. Chembio Diagnostics Inc. has signed a ...

PARIS – Biosynex SA signed a binding offer to acquire 100% of the stock in Avalun SAS, a company developing the Labpad in vitro diagnostic device that provides rapid biological test results from small ...

* FIRST SUPPLIES OF THE RAPID SEROLOGY TEST BIOSYNEX COVID-19 BSS TO ANALYTICAL LABORATORIES AND FRENCH HOSPITALS Source text: bit.ly/2RejCSz Further company coverage: ...

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide ...